| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 978 | 1,188 | 1,093 | 955 | 1,026 | 1,050 | 1,030 | 1,081 | 1,051 | 1,050 | 1,194 | 1,193 |
| Expenses | 1,095 | 1,057 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,031 | 1,008 |
| EBITDA | -117 | 131 | 103 | 14 | 135 | 138 | 141 | 120 | 156 | 127 | 163 | 185 |
| Operating Profit % | -13 % | 11 % | 9 % | 0 % | 13 % | 12 % | 12 % | 9 % | 13 % | 9 % | 11 % | 13 % |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 |
| Profit Before Tax | -159 | 87 | 59 | -33 | 88 | 92 | 91 | 75 | 96 | 66 | 100 | 121 |
| Tax | 29 | 54 | -136 | 7 | 26 | 25 | 25 | -75 | 31 | 23 | 32 | 40 |
| Net Profit | -187 | 33 | 195 | -40 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 |
| EPS in ₹ | -13.16 | 2.22 | 13.21 | -2.89 | 4.21 | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 |
Akums Drugs & Pharma
Akums Drugs & Pharma
632.30
+1.45
(0.23%)
Market Cap
9,952.02 Cr
PE Ratio
38.72
Volume
1,14,956.00
Day High - Low
640.00 - 629.30
52W High-Low
642.90 - 409.30
Key Fundamentals
Market Cap
9,952.02 Cr
EPS
16.67
PE Ratio
38.72
PB Ratio
3.00
Book Value
210.57
EBITDA
650.70
Dividend Yield
0.46 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
7.70
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Akums BRSR FY26 details ESG metrics
Jun 18, 2026
Jun 18, 2026Akums Drugs & Pharmaceuticals Ltd filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details ESG performance, including energy consumption, waste management, and employee welfare.
Akums fixes July 3 record date for dividendJun 16, 2026
Jun 16, 2026Akums Drugs and Pharmaceuticals Ltd has fixed July 3, 2026 as the record date for a final and special dividend of ₹3 per share. The payout is subject to shareholder approval at the AGM on July 10.
Akums to attend investor meets on June 15Jun 10, 2026
Jun 10, 2026Akums Drugs and Pharmaceuticals will hold investor meets in Singapore and Mumbai on June 15, 2026. No unpublished price sensitive information will be shared.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,870.60 | #1 4,48,819.60 | 38.90 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 61.23 | |
6,688.50 | 1,77,558.66 | 67.64 | 10,560.00 | 8.73 | 2,520 | 13.44 | 42.94 | |
4,669.70 | 1,58,043.87 | 73.47 | 13,886.20 | 20.34 | 2,138 | -26.91 | 63.51 | |
1,458.90 | 1,17,856.55 | 30.48 | 29,044.60 | 2.24 | 3,870 | -55.32 | 66.61 | |
1,354.90 | 1,13,089.31 | 26.89 | 33,593.30 | -0.44 | 3,998 | -86.05 | 60.09 | |
1,097.40 | 1,10,424.12 | 21.78 | 26,719.70 | 13.65 | 5,242 | 7.82 | 61.31 | |
2,391.10 | 1,09,328.87 | #1 20.46 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 63.18 | |
2,494.00 | 1,03,001.20 | 53.06 | 14,277.60 | 12.03 | 1,750 | 31.75 | 57.28 | |
1,552.70 | 89,338.93 | 25.75 | 33,384.70 | 3.21 | 3,376 | 1.99 | 62.66 | |
1,520.00 | 82,058.20 | 90.63 | 6,867.80 | #1 22.01 | 890 | 21.18 | 66.46 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
7.51 %
Net Income Growth
-25.42 %
Cash Flow Change
153.91 %
ROE
-31.37 %
ROCE
-7.29 %
EBITDA Margin (Avg.)
17.12 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 2,078 | 2,167 | 3,069 | 3,267 | 3,516 | 4,113 | 5,447 |
| Fixed Assets | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| Current Assets | 1,250 | 1,157 | 1,864 | 1,879 | 1,941 | 2,275 | 3,560 |
| Capital Work in Progress | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,371 | 1,226 | 2,017 | 2,066 | 2,130 | 2,553 | 3,814 |
| Total Equity & Liabilities | 2,078 | 2,167 | 3,069 | 3,267 | 3,516 | 4,113 | 5,447 |
| Current Liabilities | 730 | 580 | 1,272 | 1,266 | 1,211 | 894 | 1,095 |
| Non Current Liabilities | 627 | 700 | 1,172 | 1,278 | 1,585 | 156 | 1,021 |
| Total Equity | 721 | 887 | 625 | 723 | 721 | 3,064 | 3,331 |
| Reserve & Surplus | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Share Capital | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Investing Activities | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Operating Activities | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Financing Activities | 66 | 37 | 233 | -92 | 236 | 125 | -108 | 73 | 34 |
Share Holding
| % Holding | Feb 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 84.91 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % |
| FIIs | 0.00 % | 5.32 % | 7.34 % | 6.36 % | 5.77 % | 4.24 % | 2.28 % | 1.15 % | 1.37 % |
| DIIs | 0.00 % | 7.60 % | 7.52 % | 7.00 % | 7.40 % | 8.85 % | 9.28 % | 14.40 % | 14.35 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.43 % | 2.11 % | 3.33 % | 3.41 % | 3.60 % | 5.01 % | 5.51 % | 5.34 % |
| Others | 15.09 % | 7.38 % | 7.77 % | 8.05 % | 8.16 % | 8.05 % | 8.18 % | 3.68 % | 3.68 % |
| No of Share Holders | 8 | 1,38,205 | 57,531 | 68,410 | 69,366 | 69,424 | 75,365 | 76,869 | 72,589 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 10 Jul 2026 |  Annual General Meeting | NA | 10 Jul 2026 | 540.35 | 630.75 |
| 03 Jul 2026 |  Dividend | ₹ 2.00 /share | 03 Jul 2026 | 540.35 | 630.75 |
| 03 Jul 2026 | Dividend | ₹ 1.00 /share | 03 Jul 2026 | 540.35 | 630.75 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 845.30 | 796.60 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 566.55 | 570.30 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 546.50 | 566.05 |
| 18 Jul 2025 | Annual General Meeting | NA | 18 Jul 2025 | 566.05 | 559.90 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 513.90 | 490.80 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 454.45 | 453.15 |
| 13 Feb 2026 | Quarterly Result Announcement | NA | 13 Feb 2026 | 439.55 | 464.00 |
| 14 May 2026 | Quarterly Result Announcement | NA | 14 May 2026 | 557.20 | 540.35 |
Announcements
Closure of Trading Window7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Jun 19, 2026Notice And Integrated Annual Report For The Financial Year 2025-26 To Those Members Who Have Not Registered Their E-Mail IDSJun 19, 2026
Jun 19, 2026Business Responsibility and Sustainability Reporting (BRSR)Jun 18, 2026
Jun 18, 2026Reg. 34 (1) Annual Report.Jun 18, 2026
Jun 18, 2026Notice Of The 22Nd Annual General MeetingJun 18, 2026
Jun 18, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 16, 2026
Jun 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 10, 2026
Jun 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2026
Jun 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2026
Jun 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 28, 2026
May 28, 2026Receipt Of Assessment Order(S) By Certain Subsidiaries From Income Tax DepartmentMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2026
May 21, 2026Receipt Of Assessment Order(S) From Income Tax DepartmentMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 18, 2026
May 18, 2026Update On Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 18, 2026
May 18, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 16, 2026
May 16, 2026Update On Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 16, 2026
May 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2026
May 14, 2026Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 14, 2026
May 14, 2026Corporate Action-Board approves DividendMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
May 14, 2026Financial Results For The Quarter And Year Ended 31St March 2026May 14, 2026
May 14, 2026Recommendation Of Final Cum Special DividendMay 14, 2026
May 14, 2026Board Meeting Outcome for Outcome Of Board Meeting For Financial ResultsMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2026
May 12, 2026Board Meeting Intimation for Board Meeting IntimationMay 11, 2026
May 11, 2026ESG RatingMay 08, 2026
May 08, 2026Execution Of Lease DeedApr 29, 2026
Apr 29, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 11, 2026
Apr 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2026
Apr 04, 2026Closure of Trading WindowMar 23, 2026
Mar 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2026
Feb 19, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 13, 2026
Feb 13, 2026Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31.12.2025Feb 13, 2026
Feb 13, 2026Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th February 2026Feb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2026
Jan 31, 2026Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Nine Months Ended On 31St December 2025.Jan 31, 2026
Jan 31, 2026EU-GMP CertificationJan 23, 2026
Jan 23, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 69.06
ATR(14)
Less Volatile 20.97
STOCH(9,6)
Neutral 61.85
STOCH RSI(14)
Neutral 44.15
MACD(12,26)
Bullish 1.16
ADX(14)
Strong Trend 35.34
UO(9)
Bearish 38.62
ROC(12)
Uptrend And Accelerating 1.28
WillR(14)
Neutral -21.75
About Akums Drugs & Pharma
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and...more
Listing Date
06 Aug, 2024(1 Years,
26 days)
Website
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
